98%
921
2 minutes
20
Introduction: Venous thromboembolism (VTE) is a frequent cause of preventable harm among hospitalized patients. Many prescribed prophylaxis doses are not administered despite supporting evidence. We previously demonstrated a patient-centered education bundle improved VTE prophylaxis administration broadly; however, patient-specific factors driving nonadministration are unclear. We examine the effects of the education bundle on missed doses of VTE prophylaxis by sex.
Methods: We performed a post-hoc analysis of a nonrandomized controlled trial to evaluate the differences in missed doses by sex. Pre-intervention and intervention periods for patients admitted to 16 surgical and medical floors between 10/2014-03/2015 (pre-intervention) and 04/2015-12/2015 (intervention) were compared. We examined the conditional odds of (1) overall missed doses, (2) missed doses due to patient refusal, and (3) missed doses for other reasons.
Results: Overall, 16,865 patients were included (pre-intervention 6853, intervention 10,012), with 2350 male and 2460 female patients (intervention), and 6373 male and 5682 female patients (control). Any missed dose significantly reduced on the intervention floors among male (odds ratio OR 0.55; 95% confidence interval CI, 0.44-0.70, P < 0.001) and female (OR 0.59; 95% CI, 0.47-0.73, P < 0.001) patients. Similar significant reductions ensued for missed doses due to patient refusal (P < 0.001). Overall, there were no sex-specific differences (P-interaction >0.05).
Conclusions: Our intervention increased VTE prophylaxis administration for both female and male patients, driven by decreased patient refusal. Patient education should be applicable to a wide range of patient demographics representative of the target group. To improve future interventions, quality improvement efforts should be evaluated based on patient demographics and drivers of differences in care.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.jss.2022.07.015 | DOI Listing |
Nutr J
September 2025
Department of Life Sciences, Division of Food and Nutrition Science, Chalmers University of Technology, Gothenburg, 412 96, Sweden.
Background: Avenanthramides (AVAs) and Avenacosides (AVEs) are unique to oats (Avena Sativa) and may serve as biomarkers of oat intake. However, information regarding their validity as food intake biomarkers is missing. We aimed to investigate critical validation parameters such as half-lives, dose-response, matrix effects, relative bioavailability under single dose, and in relation to the abundance of Feacalibacterium prausnitzii, and under repeated dosing, to understand the potential applications of AVAs and AVEs as biomarkers of oat intake.
View Article and Find Full Text PDFBMJ Neurol Open
September 2025
Wolfson Institute of Population Health, Queen Mary University of London, Centre for Preventive Neurology, London, England, UK.
Background: Nitrous oxide (N₂O)-related neurotoxicity is a significant public health concern among young people in the UK. Recognition necessitates timely diagnosis, abstinence from N₂O consumption and replacement of vitamin B12, usually via intramuscular (IM) hydroxocobalamin. This service development project evaluated a self-injection programme (SIP) compared with a nurse-led approach, within an established ambulatory care pathway, with the aim of improving treatment adherence and completion.
View Article and Find Full Text PDFAm J Med
September 2025
Russell H. Morgan Department of Radiology and Radiological Science; Department of Oncology; Department of Urology; Johns Hopkins University School of Medicine, Baltimore, MD, Johns Hopkins Health System, Baltimore, MD. Electronic address:
Prior authorization requirements by health insurance plans have become a barrier to healthcare delivery in the United States in terms of clinical efficiency, patient and provider experience. Surveyed physicians report associations with care delays, reduced clinical effectiveness and compromised patient outcomes. In this systematic review, we synthesized the published evidence regarding harmful effects of prior authorization on disease management and patient outcomes.
View Article and Find Full Text PDFAdv Ther
September 2025
Tolley Limited, Derbyshire, UK.
Introduction: Relative dose intensity (RDI) and dose delay factor (DDF) are important variables in cost-effectiveness analyses of oncology drugs that impact incremental cost-effectiveness ratios (ICERs). However, there is little published evidence on how RDI and DDF affect ICERs and how the calculation and application of these measures vary across health technology appraisals (HTAs). To understand this further, we analyzed National Institute for Health and Care Excellence (NICE) HTAs.
View Article and Find Full Text PDFIntroduction: Donanemab is an immunoglobulin G1 antibody that targets an N-terminal truncated form of amyloid beta present in mature plaques. Treatment-emergent (TE) anti-drug antibodies (ADAs) were quantified in donanemab-treated participants from two pivotal clinical trials, and effects of TE ADAs on donanemab pharmacokinetics, efficacy, and safety were assessed.
Methods: Data were pooled from the phase 2 TRAILBLAZER-ALZ (NCT03367403) and phase 3 TRAILBLAZER-ALZ 2 trials (NCT04437511).